Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E. — Clinical Trial Site

80 Registered trials

43 Currently recruiting

Organisation

Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E.

Location

Lisbon, Portugal

Identifier

ORG-100029371

Address

Rua Professor Lima Basto, 1099-023, Portugal

Departments

2104: Serviço de Oncologia Médica
2901: Serviço de Hematologia
351001: Oncologia Medica
5807:Serviço de Pneumologia
93149003:Oncologia Medica
Clinical Hematology Unit - Hematology Department
Departamento de Hematologia
Department of Hematology
Department of Medical Oncology
Haematology
Hamatology
Hemato-Oncology
Hematology
Marrow Transplant
Medical Oncology
Medical oncology - Breast
Medical oncology - Ovarian
Medical Oncology Department
N/A
Oncology
Oncology Department
Pediatric
Pediatrics
Pneumology
Pneumology Department
PT30004:Hematologia
Pulmonology
Serviço de Hematologia
Serviço de Hematologia Clínica
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria
Serviço de Pneumologia
Serviço Hematologia
Serviço Hematologia e Oncologia Médica
Surgery
Transplantação de Progenitores Hematopoiéticos/UTM
Unidade de Transplante de Medula
urology
Urology Department

Clinical trials at this site (80)

Search interface

A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Recruiting

2022-501697-19-01 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Ly 5 2024-06-18
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting

2022-500031-37-00 stage IA/IIA Hodgkin lymphoma 5 2024-04-08
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Relapsed or Refractory Marginal Zone Lymphoma 5 2023-09-01
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Acute Myeloid Leukemia 5 2023-07-14
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting

2023-510384-36-00 Newly Diagnosed Multiple Myeloma 5 2022-09-13
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli… Recruiting

2024-512671-12-00 Unresectable head and neck squamous cell carcinoma, met 10 2021-03-05
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus… Recruiting

2024-512526-28-00 Locally recurrent rectal cancer 5 2020-10-28
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Rhabdoyosarcoma 9 2020-10-07
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Acute Lymphoblastic Leukaemia 10 2020-07-13
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Metastatic leiomyosarcoma 5 2023-12-12
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended

2023-503652-27-00 Melanoma 5 2023-10-06